Beijing, China

Panliang Gao

USPTO Granted Patents = 3 

 

Average Co-Inventor Count = 5.8

ph-index = 2

Forward Citations = 16(Granted Patents)


Company Filing History:


Years Active: 2020-2025

Loading Chart...
Loading Chart...
3 patents (USPTO):

Title: **Panliang Gao: Innovator in Pharmaceutical Advancements**

Introduction

Panliang Gao is a notable inventor based in Beijing, China. With a significant focus on pharmaceutical innovations, he has made substantial contributions to the field, holding three patents to his name. His work primarily revolves around the development of compounds aiding in the treatment of SHP2 mediated disorders.

Latest Patents

Among his latest innovations are patents centered on heterocyclic derivatives useful as SHP2 inhibitors. The first patent involves a novel compound of formula I, which outlines the compound's synthesis and its application in treating SHP2 mediated disorders. The second patent also focuses on pyrazine derivatives as SHP2 inhibitors, detailing the synthesis and methods for treating such disorders. These contributions underscore his commitment to advancing pharmaceutical science.

Career Highlights

Panliang Gao is currently associated with Jacobio Pharmaceuticals Co., Ltd., a company renowned for its cutting-edge research and development in the pharmaceutical sector. His inventive work continues to reflect his dedication to improving therapeutic options for patients.

Collaborations

Throughout his career, Gao has collaborated with esteemed colleagues such as Cunbo Ma and Di Kang. These partnerships enhance the innovative capabilities within the research team, leading to the development of impactful medical solutions.

Conclusion

Panliang Gao stands out as an influential inventor in the realm of pharmaceuticals, with a specific focus on SHP2 inhibitors. His patents not only demonstrate his innovative spirit but also contribute significantly to the ongoing fight against complex disorders. Such contributions are invaluable to the advancement of medical science and therapeutics.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…